When, if ever, would you consider use of nivo/ipi for favorable risk metastatic ccRCC?  

Or with other available IO/TKI combinations should this be strictly reserved for intermediate/high risk patients only? 

If selecting IO/TKI, do you have a preferred regimen? 



Answer from: Medical Oncologist at Community Practice

Answer from: Medical Oncologist at Community Practice

Answer from: Medical Oncologist at Academic Institution

Answer from: Medical Oncologist at Academic Institution

Answer from: Medical Oncologist at Community Practice